11630 SW 97 Street, Miami, Florida 33176, US

Advertising Driven Press Release Distribution

Tag: cancer

Limitless Venture Group, Inc. and subsidiary Rokin Inc. solidify plans to make Rokin Vapes the industry leader in the projected 26.52 Billion Dollar Cannabis and CBD vaporizer markets.

Press Release
TULSA, OK / ACCESSWIRE /October 14, 2021 / Limitless Venture Group, Inc. (OTC PINK: LVGI) (“LVGI” or the “Company”), a publicly traded holding company that provides its shareholders with access to investment opportunities in small and medium-sized businesses uniquely positioned for rapid growth, is pleased to announce today that it has made a strategic commitment to fund its fast growing subsidiary Rokin, Inc. (“Rokin”) for the next four years with. Read More>>

CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO

Press Release
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, October 12, 2021 -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Dr. Catherine Sohn has joined the Company as a Special Advisor to the Board of. Read More>>

CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE

Press Release
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, October 7, 2021 - Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached agreement with Mid- Atlantic  BioTherapeutics (MABT)  to  broaden  its  previously  announced  license  of  IMT504,   a novel patented immunotherapy and adjuvant, to include the development of a next generation COVID-19 vaccine.. Read More>>

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report 2035: Competitive Landscape and Market Forecast to 2035 | DelveInsight

Press Release
DelveInsight's 'Neoantigen based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035' report provides an in-depth understanding of Neoantigen based Personalized Cancer therapeutic Vaccines & the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some key facts of Neoantigen-based Personalized Cancer Therapeutic Vaccines Market are: Expected launch of potential therapeutic Neoantigen-based Personalized Cancer Therapeutic. Read More>>

The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030, predicts Roots Analysis

Press Release
Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access Roots Analysis is pleased to announce the publication of its recent study, titled, “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA,. Read More>>

Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis

Press Release
Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.” The report features an extensive study of the current landscape and future. Read More>>

Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis

Press Release
Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.” The report features an extensive study of the current landscape and future. Read More>>

Water Tower Research to Host Theratechnologies CEO Paul Lévesque and CMO Christian Marsolais as Part of the WTR Fireside Chat Series

Press Release
The Fireside Chat will take place on Wednesday, February 10th at 2:00 pm Eastern Time. The live event will also be archived and available for replay. The Fireside Chat is open for all investors to access. “We are excited to host the CEO and CMO from Theratechnologies Inc. following the FDA fast-track designation announced by the company on February 4, 2021 for its lead peptide-drug conjugate TH1902. This designation is. Read More>>

Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis

Press Release
Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions   Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.”   The report features an extensive study of the current landscape. Read More>>

Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis

Press Release
 Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.” The report features an extensive study of the current landscape and future. Read More>>

Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma

Press Release
Boca Raton, FL (October 16, 2020) – Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody (mAB) in an antibody-drug conjugate to. Read More>>

Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Press Release
Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases, announced today the Company has signed a definitive agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT) to acquire worldwide rights for the development of IMT504, a novel, patented immunotherapy, to treat symptomatic rabies. IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can. Read More>>

Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets

Press Release
Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, have entered into a collaboration agreement to develop new targeted theranostic (diagnostic and therapy) products for a broad range of cancer types. Clarity and ImaginAb will combine their proprietary technologies to develop novel minibody and cys-diabody. Read More>>

BRAVE & BEAUTIFUL BLOOD CANCER FOUNDATION NON-PROFIT PARTNERS WITH CITY OF LAS VEGAS FOR 1ST ANNUAL HEALTH FAMILIES FESTIVAL

Press Release
The Brave & Beautiful Blood Cancer Foundation announces its 1st annual Healthy Families Festival featuring a 1 Mile Warrior Walk in a Fight to End Blood Cancer The Brave & Beautiful Blood Cancer Foundation partners with The City of Las Vegas for it's 1st Annual Healthy Families Festival. The event will be free to all and features a 1 Mile Warrior Walk raising funds to bring awareness to blood cancer. Read More>>

Lloyd Bell Settles Medical Malpractice Case Against Kaiser Permanente

Press Release
Lloyd Bell Settles Medical Malpractice Case Against Kaiser Permanente 24-Year-Old Male Dies After Kaiser Doctors Fail to Diagnose Testicular Cancer for 6 Months ATLANTA, Ga. – October 25, 2019 – Lloyd Bell of Bell Law Firm, Georgia’s preeminent law firm for victims of medical malpractice, today confirms the settling of a wrongful death case against Kaiser Permanente for a confidential sum. The settlement concludes the lawsuit brought by the widow. Read More>>

Cancer Treatment Drugs Market by Type, Top Key Players, Size, Share, Growth, Trends – Opportunity, Analysis, Forecast 2025

Press Release
Cancer Drugs and Treatment Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy Biologic Therapy, Hormonal Therapy and Others. The classification of cancer treatment drugs includes chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others, and the revenue proportion of chemotherapy in 2016 is about 51%.Cancer treatment drugs are. Read More>>

Subscribe to Our Newsletter

For exclusive content regarding the latest trends in the world of Press Release distribution.